25 Jun 2026

CRC Research Update — June 25, 2026

Creator: The CRC Digest
Published: 2026-06-25T13:34:35Z

Today's colorectal cancer research highlights

Was this forwarded to you? Read on the web or subscribe free

IMPORTANT: The CRC Digest curates and summarizes publicly available research for informational and educational purposes only. Nothing in this newsletter constitutes medical advice, diagnosis, or treatment recommendation. The information provided should not be used as a substitute for professional medical advice. Always seek the guidance of your physician or other qualified health provider with any questions regarding a medical condition or treatment. Content is generated with AI assistance and reviewed by the editorial team. We are not medical professionals. Individual results, treatments, and outcomes vary.

Signal Key

TRIAL DATA clinical trial results, efficacy data, survival endpoints TREATMENT new treatment options, regimen changes, combination therapies REGULATORY FDA/EMA approvals, guideline updates, NCCN/ESMO changes RESEARCH cancer biology, biomarker discoveries, resistance pathways SCREENING screening, colonoscopy guidelines, liquid biopsy, molecular profiling LIVING WITH CRC survivorship, quality of life, side effects, patient decision-making, caregiver support

CRC Research Update

KRAS Peptide Vaccine Shows Promise in Phase I Trial for MSS Colorectal Cancer
A phase I trial of mKRAS-VAX, a pooled mutant KRAS peptide vaccine targeting six KRAS mutations, combined with nivolumab and ipilimumab in 13 patients with pretreated metastatic MSS colorectal cancer met both primary endpoints of safety and immunogenicity. (Nature Communications)
FIT Screening Shows Similar Yield in Adults 45-49 vs. 50-54
A provincial screening program in China found that fecal immunochemical test screening outcomes, including positivity rates and detection rates of advanced colorectal neoplasia, were comparable between adults aged 45-49 and 50-54 years, supporting earlier screening initiation. (American Journal of Gastroenterology)
Liquid Biopsy Detects RAS Mutation Clearance After Bevacizumab Treatment
In a prospective study of 58 metastatic colorectal cancer patients with baseline RAS mutations, plasma samples collected at progression after first-line bevacizumab-based chemotherapy were analyzed using liquid biopsy to evaluate RAS mutation status and assess the prognostic significance of mutation clearance. (Clinical and Translational Oncology)
Cell Therapy Shows Promise in Third-Line MSS Colorectal Cancer
A phase 2B trial evaluated AlloStim®, an allogeneic activated memory Th1 cell therapy designed to convert "cold" tumors to "hot," in third-line MSS/pMMR metastatic colorectal cancer patients. (Translational Oncology)

🔬 Under 50 Spotlight

Research relevant to early-onset and younger CRC patients

FIT Screening Effective in 45-49 Age Group
A Chinese screening program found comparable detection rates of advanced colorectal neoplasia between adults aged 45-49 and 50-54 years. (American Journal of Gastroenterology)
Immunotherapy Shows Response in Pediatric CMMRD-Associated CRC
A 10-year-old with constitutional mismatch repair deficiency-associated colorectal adenocarcinoma received neoadjuvant ipilimumab and nivolumab, achieving partial response. (Journal of Pediatric Hematology/Oncology)

🧬 Biomarker Spotlight

Research by genetic subtype — KRAS, BRAF, MSI-H, HER2, and more

KRAS G13C Inhibitor Reveals Unique Biology of Codon 13 Mutations
RMC-8839, a covalent KRAS G13C inhibitor, induced tumor regressions in selected xenograft models, but one-third of cell lines showed incomplete pathway suppression, revealing that codon 13-mutant RAS differs from other KRAS mutations with decreased stability and increased GTP hydrolysis. (Cancer Discovery)
Colonoscope-Derived Mucus Detects KRAS Mutations in Precancerous Lesions
A prospective pilot study found that mucus collected from the colonoscope sheath during routine colonoscopy serves as a high-fidelity source of cell-free DNA for detecting KRAS-mutated colorectal neoplasia. (Translational Oncology)

Research continues to advance our understanding of colorectal cancer across screening, treatment, and biomarker discovery.

CRC Research Update

Subscribe to The CRC Digest